Venrock Adviser, LLC

NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$2.06B2026 Q3
Positions34
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.71.0%

Venrock Adviser, LLC reported 34 positions worth $2.06B as of September 30, 2026 (13F filed November 16, 2026). Largest holding: ORKA (16.8%). Biggest move: exit APOGEE THERAPEUTICS INC ($1.13B).

10 / 34 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 ORKAOruka Therapeutics$345.5M16.79%4,148,428——+19.1%
▸ 2 ERASErasca$294.5M14.31%20,089,932———
▸ 3 SYRESpyre Therapeutics$221.3M10.75%2,485,448——+16.8%
▸ 4 KRSAKorsana Biosciences$145.6M7.07%4,549,585———
▸ 5 SVRASavara$101.0M4.91%19,568,534——-10.1%
▸ 6 OCULOcular Therapeutix$79.4M3.86%10,346,926——-21.6%
▸ 7 DMRADamora Therapeutics$76.7M3.73%3,603,595——+1.5%
▸ 8 DNTHDianthus Therapeutics$72.4M3.52%822,020——+1.7%
▸ 9 VRDNViridian Therapeutics$67.1M3.26%3,257,917——+49.9%
▸ 10 VORVor Biopharma$58.0M2.82%3,041,719——-0.6%

Pro Feature

The remaining 24 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Venrock Adviser, LLC hold as of Q3 2026?

Venrock Adviser, LLC reported 34 positions worth $2.06B in its Q3 2026 13F filing. Largest positions: ORKA (16.8%), ERAS (14.3%), SYRE (10.8%), KRSA (7.1%) and SVRA (4.9%).

What did Venrock Adviser, LLC buy in Q3 2026?

New positions: KRSA, DMRA, ADRX, ARVN and ENTERA BIO LTD (7 in all). Added to: ERAS, SVRA, ACHV, XFOR and RLMD (7 in all).

What did Venrock Adviser, LLC sell in Q3 2026?

Reduced: SYRE, DNTH, ORIC, KRRO and MAZE. Sold out entirely: APOGEE THERAPEUTICS INC , DAMORA THERAPEUTICS INC , ELVN, HELP and CTMX (6 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.